Ann: Successful Completion of $30m Placement, page-31

Referencing Luke 9:23 And he said to them all, If any man will come after me, let him deny himself, and take up his cross daily, and follow me.

Minority retail shareholders could have benefited from a better better price if the raise was timed after sub-milestones:
1) VP-001 patient recruitment completed May23
2) VP-001 first dose May23
3) VP-001 BIO conference June 23
4) PYC-001 Tox studies results

This is the way, whether I/we ‘feel’ we’ve be done right or wrong (how far the price is from intrinsic value, the dilution, price suppression, insiders/SIs vs outsiders/retail…) the question is whether there is Truth in what we’re following.

On that note:

1) VP-001 timelines updated as per the TIDES poster below may be of interest to the patience required from us. Today’s Ann will fade to be one of many future ripples in the pond until the appointed day.



2) PYC-001 significant differentiation highlighted.

In a way it helps to go head to head with Stoke (770m MC) to see how the two leads and their respective platforms perform in efficacy readouts. I believe spotlight will be shone brighter on PYC as the ADOA lead progresses: